Table 2. Clinical trials of concurrent TOP1 drugs with thoracic radiotherapy for SCLC.
Study description |
No. of patients | Chemotherapy regimen |
Radiation dose | Toxicity | Response |
---|---|---|---|---|---|
Phase I (52) | 17 (all LS) | Irinotecan + cisplatin | 60 Gy in 3 split courses of 20 Gy in 10 daily fractions | Fatigue | 94% (4 CR, 11 PR) |
Phase II (53) | 100 (43 LS, 57 ES) | Topotecan + carboplatin +paclitaxel | 45 Gy in 25 daily fractions for LD | Neutropenia, thrombocytopenia, fatigue | LS -93% ES -88% |
Phase II (54) | 78 (all LS) | Topotecan + carboplatin +paclitaxel | 61.2 Gy in 34 daily fractions | Neutropenia, thrombocytopenia, fatigue fatal pneumonitis | 51% CR SV: 20 months |
SCLC = small cell lung cancer; LS = limited-stage; ES = extensive-stage; CR = complete response; SV = median survival.